Glaukos Announces FDA 510(k) Clearance of iStent infinite&#x

MIGS Founder Leads with the First-Ever Micro-Invasive Implantable Device for Standalone Glaucoma TreatmentNovel Three-Stent Injectable System Designed to Provide Foundational, 24/7 IOP ControlALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical c...

Related Keywords

Chris Lewis , Thomas Burns , Exchange Commission , Glaukos Corporation , Drug Administration , Investor Relations Corporate Affairs , First Ever Micro Invasive Implantable Device , Standalone Glaucoma , Three Stent Injectable System Designed , Provide Foundational , Trabecular Micro Bypass System , Micro Invasive Glaucoma Surgery , Quarterly Report , Investor Section , Investor Relations , Corporate Affairs ,